Redx, a drug discovery and development company focused on cancer and fibrosis, conditionally raised circa £25.5m through a placing of new Ordinary Shares with both new institutional investors and existing shareholders and up to a further approximately £2.2m million by way of an Open Offer.   Iain Ross, Chairman of Redx, commented: “We are delighted … Continue reading AIM-listed MedTech Redx raises £25.5m